Sodexo Canada: The global leader who believes the difference a day makes
Founded in Marseille in 1966, and now operating in 53 countries, Sodexo provides facilities services that drive positive
Barclay Restorations DKI: The longest running insurance restoration company in Greater Vancouver
Locally owned-and operated and serving Metro Vancouver and the Fraser Valley, Barclay Restorations DKI is a full-service restoration CDW Canada: Helping small businesses use IT security to prepare, defend, and respond
Established in 2003, CDW Canada is a leading provider of technology solutions for business, government, education, and healthcare, Stamped Engineering Corporation: High quality, fit for purpose engineering services
Specializing in design engineering that is customized to the needs of the client, Stamped Engineering Corporation is a Alpine Building Maintenance: Customized cleaning solutions
Founded in 1980 in the interior of British Columbia, family-owned building services company Alpine Building Maintenance has evolved Case Design/Remodeling Halifax: Flawless design and execution
With two decades of experience, Case Design/Remodeling is a design-build renovation, remodeling, project and construction management team serving Weston Wood Solutions: One of Canada’s fastest growing companies
An innovative supplier of lumber and engineered wood products to window and door manufacturers in the Americas, Europe CDW Canada: Helping organizations navigate a complex IT market
Established in 2003, CDW Canada is a leading provider of technology solutions for business, government, education, and healthcare,-
Reclaiming Canada’s key service export: Tourism
Tourism is an increasingly dynamic sector of the global economy; pre-2019 tourism was a $1.4 trillion industry generating Concerning signs for Canada’s construction sector in 2023
Coming into 2022, construction contractors had never been more optimistic about the state of the industry. Independent Contractors Strengthening your organization through sustainability & ESG
It’s no secret that organizations are increasingly feeling the pressure to respond to social and environmental imperatives. More 55% of provincial healthcare budgets will be for seniors by 2030
Canada’s straining health care system is dominating headlines, as provinces pit themselves against the federal government in a Spymasters, conspiracies, the PRC, & Dong Jingwei
The tensions currently exposed between the People’s Republic of China (PRC) and the United States, let alone the Digital transformations on the wrong end of the stick
There’s a growing body of evidence demonstrating technology-led digital transformations are overpromising and under-delivering returns on investment for It’s impossible to tackle climate change without nuclear
The task of tackling climate change is mammoth. It requires an ‘all-in’ approach among Canada’s business leaders, governments, Inflation: Demand creates its own supply
The point has to be made that while we clearly have a stickier inflation situation on our hands,
ACERUS ANNOUNCES LICENSING OF NATESTO® IN MAJOR EUROPEAN COUNTRIES
Acerus Pharmaceuticals Corporation (TSX:ASP) has announced the signing of an agreement granting medac Gesellschaft für klinische Spezialpräparate mbH (“medac”) the exclusive right to market NATESTO® in 15 European countries (Germany, United Kingdom, France, Italy, Czech Republic, Slovakia, Spain, Sweden, Finland, Denmark, Norway, Poland, Austria, Netherland and Belgium). medac is a German pharmaceutical company with business in 80 countries and more than 1,200 employees worldwide.
“We are delighted to be partnering with medac for the commercialization of NATESTO® in Europe,” said Tom Rossi, President and Chief Executive Officer of Acerus. “Their extensive reach and commercial expertise within the speciality pharmaceutical sector will be a key advantage as we aim to maximize the full potential of NATESTO®. This agreement represents a significant milestone for Acerus as we continue to execute on our strategy of expanding the brand’s reach on a global scale.”
“We are very pleased to announce this partnership with Acerus as it enables us to provide patients in Europe with an innovative product and address a medical need,” said Dr. Ulrich Kosciessa, Managing Director of medac. “NATESTO® is an important advance for patients suffering from hypogonadism. Its novel nasal administration and unique safety and efficacy profile represent a clear opportunity to improve patient quality of life and represents a perfect fit to our current portfolio. We look forward to working closely with Acerus as we prepare to file NATESTO® for European marketing approval.”
Under the terms of the agreement, Acerus will receive a non-refundable upfront fee and regulatory milestone payments upon medac receiving marketing approval in certain countries as well as milestone payments based on achieving sales targets. In total, Acerus is eligible to receive up to €11,500,000 in upfront and milestone payments. Acerus will oversee the manufacturing of NATESTO® and, in addition, will receive a supply price for the product. If approved, NATESTO® will be the first and only testosterone nasal gel for androgen replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism) in Europe.
- Read the current edition
- Recent posts
